Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.71
-0.0100-0.58%
Post-market: 1.750.0400+2.34%19:40 EDT
Volume:385.59K
Turnover:668.85K
Market Cap:74.63M
PE:-3.36
High:1.78
Open:1.75
Low:1.70
Close:1.72
52wk High:4.34
52wk Low:1.53
Shares:43.64M
Float Shares:42.34M
Volume Ratio:0.55
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5092
EPS(LYR):-0.6115
ROE:-268.30%
ROA:-95.51%
PB:6.61
PE(LYR):-2.80

Loading ...

U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,

Reuters
·
Aug 11

Gain Therapeutics Climbs on Narrower-than-Expected Quarterly Loss

Reuters
·
Aug 11

Gain Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs

Reuters
·
Aug 11

Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate

Benzinga Earnings
·
Aug 11

Gain Therapeutics Q2 Net Loss Per Share Narrows as R&D Expenses Fall

Reuters
·
Aug 11

Gain Therapeutics reports Q2 EPS (11c), consensus (15c)

TIPRANKS
·
Aug 11

Gain Therapeutics Q2 EPS USD -0.11

THOMSON REUTERS
·
Aug 11

Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Dow Jones
·
Aug 11

Gain Therapeutics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Gain Therapeutics Extends Cash Runway Into 2027 Operations

TIPRANKS
·
Jul 17

Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Promotes Terenzio Ignoni to COO

Reuters
·
Jul 16

Gain Therapeutics - to Commence Phase 2 Study of Rexaceract in Q3 2026

THOMSON REUTERS
·
Jul 16

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

THOMSON REUTERS
·
Jul 16

Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged

TIPRANKS
·
Jul 03

Analysts’ Opinions Are Mixed on These Healthcare Stocks: LivaNova (LIVN), Gain Therapeutics (GANX) and Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jul 02

Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained

TIPRANKS
·
Jul 01

Gain Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Jul 01

Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines

Dow Jones
·
Jun 30

Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial

TIPRANKS
·
Jun 30